ceritinib

Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.

Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable, ATP-competitive inhibitor of ALK tyrosine kinase (IC50 of 200 pM) and also inhibits IGF-1R, InsR, and STK22D [IC50 values of 8, 7, and 23 nM, respectively], demonstrating significant antitumor potency.

Ceritinib-platinum(IV)-4-phenylbutyrate (complex 7) is a Ceritinib-conjugated Platinum(IV) prodrug with anticancer properties. It can induce S phase arrest, DNA damage response, and apoptosis. In cancer cell models, Ceritinib-platinum(IV)-4-phenylbutyrate exhibits cytotoxicity, immune activation, and anti-invasion effects. This compound is applicable in cancer research, such as in non-small cell lung cancer (NSCLC).

Ceritinib-amide-C3-acid is a ligand-linker conjugate of a target protein. It consists of the protein ligand Ceritinib and a linker used for connecting an E3 ligase ligand. Ceritinib-amide-C3-acid is useful in the synthesis of [TD-004].

Ceritinib impurity 5 is an impurity of Ceritinib.

c-Ceritinib TFA salt is a coupleable ceritinib analog with a linker which also binds multiple other kinases, including FAK1, RSK1/2, ERK1/2, CAMKK2 and FER.

Ceritinib (Standard) is a reference standard for research and analysis in studies involving Ceritinib. Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.